Aims: To determine factors for switching to osmotic release oral system methylphenidate
(OROS‐MPH) among poor adherents to immediate‐release methylphenidate (IR‐MPH); and …

Objectives: The purpose of this study was to identify the optimal dose of osmotic release oral
system methylphenidate (OROS-MPH) using a dosage forced-titration scheme to achieve …

This study examined the efficacy and safety of osmotic release oral system methylphenidate
(OROS MPH) as compared with immediate-release MPH (IR MPH) in children with attention …

Objectives: To identify the determinants of adherence to immediate-release (IR)
methylphenidate in children and adolescents with attention-deficit/hyperactivity disorder …

Objective The objective of this study was to evaluate the efficacy and safety of
methylphenidate HCL OROS extended-release (OROS-MPH) among children with attention …

Aim: To determine the differences in the remission rate, recovery rate, functional
improvement, and treatment adherence related to treatment with short‐acting immediate …

Objective: The purpose of this study was to compare the short-term efficacy, tolerability, and
1-year adherence in Chinese children and adolescents with attention-deficit/hyperactivity …

Objectives This study evaluated neurocognitive changes after switching from immediate
release forms of methylphenidate (MPH‐IR) to osmotic release oral system methylphenidate …

Aim The aim of this study was to assess the impact of switching from immediate-release (IR)
methylphenidate (MPH) to OROS® MPH (CONCERTA®), a once-daily long-acting MPH …

Background: To explore the clinical outcomes of children/adolescents with ADHD who
transitioned from extended-release methylphenidate (ER MPH, Medikinet Retard) to osmotic …